Literature DB >> 7035781

Vasopressin treatment of cognitive dysfunction in progressive dementia.

H Weingartner, W Kaye, P Gold, S Smallberg, R Peterson, J C Gillin, M Ebert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7035781     DOI： 10.1016/0024-3205(81)90531-2

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  7 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Effects of D-Met2, Pro5-enkephalinamide on pain tolerance and some cognitive functions in man.

Authors:  J I Székely; K Török; I Karczag; J Tolna; M Till
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Hormones and cognition: current concepts and issues in neuropsychology.

Authors:  D M Erlanger; K C Kutner; A R Jacobs
Journal:  Neuropsychol Rev       Date:  1999-12       Impact factor: 7.444

Review 4.  Amnestic disorders. Pathophysiology and patterns of memory dysfunction.

Authors:  K R Erickson
Journal:  West J Med       Date:  1990-02

5.  Cerebrospinal fluid vasopressin in neurological and psychiatric disorders.

Authors:  P S Sørensen; A Gjerris; M Hammer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-01       Impact factor: 10.154

6.  The effect of vasopressin treatment on learning in Down's syndrome.

Authors:  J Eisenberg; R Hamburger-Bar; R H Belmaker
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

7.  Hypothalamic neuropeptides and memory.

Authors:  T B van Wimersma Greidanus; J Jolles; D De Wied
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.